Payer KOL Says Expect “Levers” To Limit Early Uptake Of NASH Drugs

 
• By Joseph Haas
  
Expectatinos Note on board
Payer pushback is expected when the first NASH therapies reach market due to the disease's high prevalence

More from Strategy

More from Business